Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: A case control study

Journal of Infection and Chemotherapy

Volumn 21, Issue 2, 2015, Pages 90-95

  Chusri, Sarunyou ^a   Silpapojakul, Kachornsakdi ^a   McNeil, Edward ^a   Singkhamanan, Kamonnut ^a   Chongsuvivatwong, Virasakdi ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Acinetobacter baumannii; Antibiotic exposure; Carbapenem resistance; Risk factors

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFOPERAZONE; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; CORTICOSTEROID; GENTAMICIN; IMIPENEM; OFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; PREDNISOLONE; SULBACTAM; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; FEMALE; GASTROSCOPY; GYNECOLOGY; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RISK FACTOR; SURGICAL INFECTION; TERTIARY CARE CENTER; THAILAND; URINARY TRACT INFECTION; ACINETOBACTER INFECTIONS; AGED; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CROSS INFECTION; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84928346170     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.10.002     Document Type: Article

References (37)

1. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004, 10(SUPPL.):S122-S129.
2. Farr B.M., Salgado C.D., Karchmer T.B., Scherertz R.J. Can antibiotic-resistant nosocomial infections be controlled?. Lancet Infect Dis 2001, 1:38-45.
3. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
4. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(SUPPL.):S82-S89.
5. Burke J.P. Infection control-a problem for patient safety. NEngl J Med 2003, 348:651-656.
6. Tacconelli E., De Angelis G., Cataldo M.A., Pozzi E., Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. JAntimicrob Chemother 2008, 61:26-38.
7. Y1 Carmeli, Troillet N., Eliopoulos G.M., Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999, 43:1379-1382.
8. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003, 63:2157-2168.
9. Joseph J., Rodvold K.A. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008, 9:561-575.
10. Rice L.B. The Maxwell Finland lecture: for the duration-rational antibiotic administration in an Era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008, 46:491-496.
11. File T.M. Duration and cessation of antimicrobial treatment. JHosp Med 2012, 7:S22-S33.
12. D'Agata E.M.C., Magal P., Olivier D., Ruan S., Webb G.F. Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. JTheor Biol 2007, 249:487-499.
13. Fekih Hassen M., Ayed S., Ben Sik Ali H., Gharbi R., Marghli S., Elatrous S. Duration of antibiotic therapy for ventilator-associated pneumonia: comparison of 7 and 10 days. Ann Fr Anesth Reanim 2009, 28:16-23.
14. Hedrick T.L., McElearney S.T., Smith R.L., Evans H.L., Pruett T.L., Sawyer R.G. Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. Surg Infect - Larchmt 2007, 8:589-597.
15. Engle W.D., Jackson G.L., Sendelbach D., Ford D., Olesen B., Burton K.M., et al. Neonatal pneumonia: comparison of 4 vs 7 days of antibiotic therapy in term and near-term infants. JPerinatol 2000, 20:421-426.
16. Chastre J., Wolff M., Fagon J.Y., Chevret S., Thomas F., Wermert D., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
17. Capellier G., Mockly H., Charpentier C., Annane D., Blasco G., Desmettre T., et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 Days of antibiotic treatment. PLoS One 2012, 7:e41290.
18. Singh N., Rogers P., Atwood C.W., Wagener M.M., Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
19. Higgins P.G., Dammhayn C., Hackel M., Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. JAntimicrob Chemother 2010, 65:233-238.
20. Lee S.O., Kim N.J., Choi S.H., Hyong Kim T., Chung J.W., Woo J.H., et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004, 48:224-228.
21. Abbo A., Navon-Venezia S., Hammer-Muntz O., Krichali T., Siegman-Igra Y., Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005, 11:22-29.
22. Ye J.J., Huang C.T., Shie S.S., Huang P.Y., Su L.H., Chiu C.H., et al. Multidrug resistant Acinetobacter baumannii: risk Factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010, 5:e9947.
23. Tsai H.T., Wang J.T., Chen C.J., Chang S.C. Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units. Diagn Microbiol Infect Dis 2008, 62:298-305.
24. Jamulitrat S., Thongpiyapoom S., Suwalak N. An outbreak of imipenem-resistant Acinetobacter baumannii at Songklanagarind Hospital: the risk factors and patient prognosis. JMed Assoc Thai 2007, 90:2181-2191.
25. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing: 14th informational sUPPLement 2010, NCCLS Document, Wayne, PA, M100-S14.
26. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
27. Leung W.S., Chu C.M., Tsang K.Y., Lo F.H., Lo K.F., Ho P.L. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006, 129:102-109.
28. Harris A.D., Karchmer T.B., Carmeli Y., Samore S.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001, 32:1055-1061.
29. Harris A.D., Samore M.H., Lipsitch M., Kaye K.S., Perencevich E., Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002, 34:1558-1563.
30. Malathum K., Dejsirilert S,Thongmali O. Growing problem of multidrug-resistant Acinetobacter baumannii in Thailand. Reg Health Forum 2011, 15:87-91.
31. Poirel L., Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006, 12:826-836.
32. Digranes A., Dibb W.L., Benonisen E., Salveson A. Ro 17-2301: invitro comparison with aztreonam, imipenem, ceftazidime, cefotaxime and netilmicin. Chemotherapy 1985, 31:279-285.
33. Zemelman R., Bello H., Dominguez M., Gonzalez G., Mella S., Garcia A. Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals. JAntimicrob Chemother 1993, 32:413-419.
34. Daikos G.K., Kontomichalou P., Bilalis D., Pimenidou L. Intestinal flora ecology after oral use of antibiotics: terramycin, chloramphenicol, ampicillin, neomycin, paromomycin, aminodidin. Chemotherapy 1968, 13:146-160.
35. Yoshioka H., Fujita K., Maruyama S., Oka R. Changes in aerobic pharyngeal flora related to antibiotic use and the emergence of gram-negative bacilli. Clin Pediatr - Phila 1982, 21:460-462.
36. Toltzis P. Colonization with antibiotic-resistant gram-negative bacilli in the neonatal intensive care unit. Minerva Pediatr 2003, 55:385-393.
37. Kaye K.S., Harris A.D., Samore M., Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005, 26:346-351.